Skip to main content
GNLX
NASDAQ Life Sciences

Genelux Q2 Loss Widens to $9.5M; Cash Runway Into Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.75
Mkt Cap
$123.311M
52W Low
$2.29
52W High
$8.535
52W Position info
20% above low
Off High info
68% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GNLX sits 20% above its 52-week low of $2.29.

Summary

Genelux's Q2 loss widened to $9.5M on higher Phase 3 trial costs, with cash runway only into Q1 2027 and a going concern warning still in place.

Updates

  1. · GlobeNewswire — Genelux reiterated topline data from the Phase 3 OnPrime/GOG-3076 trial in platinum-resistant ovarian cancer is expected in the second half of 2026, with additional dose-escalation updates from systemic lung cancer programs also expected in 2026.


Key Events · Earnings and Guidance · GNLX

  • Q2 Net Loss Widens

    Net loss of $9.5M for Q2 2026, up from $7.5M in Q2 2025, driven by a $1.8M increase in R&D expenses.

  • Phase 3 Trial Costs Surge

    R&D expenses rose 37% to $6.5M, primarily due to clinical and regulatory costs for the Phase 3 On Prime/GOG-3076 registration trial.

  • Going Concern Warning Reiterated

    The company states substantial doubt about its ability to continue as a going concern, with cash and marketable securities of $18.7M funding operations only into Q1 2027.

  • ATM Sales Continue

    Sold 120,087 shares in Q2 2026 and 105,000 shares in July 2026 under the ATM agreement, raising $0.3M in each period.


Analysis · GNLX · Life Sciences

Genelux reported a Q2 net loss of $9.5 million, up from $7.5 million a year earlier, as R&D spending jumped 37% to $6.5 million on the Phase 3 On Prime/GOG-3076 trial. The company reiterated its going concern warning and said its $18.7 million in cash and marketable securities funds operations only into the first quarter of 2027. The filing also discloses continued ATM sales and a new risk factor on 100% tariffs for patented pharmaceuticals, which could raise manufacturing costs.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GNLX was trading at $2.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.3M. The 52-week trading range was $2.29 to $8.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GNLX - Latest Insights

GNLX
Sep 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $1.87 info
Change: -$0.655 (-26%) info
Market Cap: $84.383M info
GNLX
Aug 13, 2026, 4:20 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.87 info
Change: -$0.765 (-29%) info
Market Cap: $84.383M info
GNLX
May 07, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.83
Real-time Price: $1.87 info
Change: -$0.965 (-34%) info
Market Cap: $84.383M info
GNLX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $2.53
Real-time Price: $1.87 info
Change: -$0.665 (-26%) info
Market Cap: $84.383M info
GNLX
Mar 19, 2026, 5:30 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $2.54
Real-time Price: $1.87 info
Change: -$0.675 (-27%) info
Market Cap: $84.383M info